Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years

Condition:   Mantle Cell Lymphoma (MCL) Intervention:   Sponsors:   Peking University Third Hospital;   Peking Union Medical College Hospital;   The Second Affiliated Hospital of Dalian Medical University;   Peking University First Hospital;   Beijing Tongren Hospital;   Beijing Hospital;   Beijing Tsinghua Changgeng Hospital;   China-Japa n Friendship Hospital;   307 Hospital of PLA;   Chinese PLA General Hospital;   First Affiliated Hospital of Harbin Medical University;   Harbin Medical University;   Baotou Cancer Hospital;   Beijing Shijitan Hospital, Capital Medical University;   Shanxi Province Cancer Hospi tal;   Beijing Naval General Hospital;   First Hospital of China Medical University;   Jilin Provincial Tumor Hospital;   Shengjing Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials